AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Mapfre Middlesea Plc

AGM Information Apr 28, 2023

2051_rns_2023-04-28_253e56ce-ca4a-43ad-b7f3-81be86ebe681.pdf

AGM Information

Open in Viewer

Opens in native device viewer

MMS/DSD/MSE00623

28 April 2023

The following is a Company Announcement issued by MAPFRE Middlesea plc, pursuant to the Capital Markets Rules of the Malta Financial Services Authority.

Quote

The Annual General Meeting (AGM) of MAPFRE Middlesea plc (the Company) was held today, the 28th April 2023, and the shareholders considered and approved the following resolutions:

Ordinary Resolutions

    1. that the Accounts for the financial year ended 31 December 2022 and the reports of the Directors and Auditors be considered and approved;
    1. that a final gross dividend of €0.054617 per share as recommended by the Board of Directors be considered and approved;
    1. that the appointment of KPMG as Auditors of the Company be approved and that the Board of Directors be authorised to fix their remuneration;
    1. that the maximum annual aggregate emoluments of Directors at €350,000 be approved;
    1. that Mr José Ramon Alegre, Ms Antoinette Caruana, Dr Gordon Cordina, Mr Martin Galea, Mr José Luis Jiménez, Mr José Maria del Pozo, Mr Etienne Sciberras, Mr Godfrey Swain and Mr Paul Testaferrata Moroni Viani be appointed as directors on the Board of Directors.

Ordinary Resolutions - Special Business

    1. that the Company's Compensation (Remuneration) Policy be considered and approved;
    1. that the Directors' Remuneration Report as set out in the Annual Report for Financial Year 2022 be considered and approved.

The Chairman thanked Dr Robert Suban, who did not seek re-appointment as Director, for his sterling contribution to the Company.

The appointment of Mr Godfrey Swain is subject to regulatory approval and will only become effective from the date of such approval.

No matters concerning Dr Suban or Mr Swain require disclosure in terms of the Capital Markets Rules.

At the Board Meeting convened immediately after the Annual General Meeting, Mr Martin Galea was appointed as Chairman of the Board of Directors of MAPFRE Middlesea plc.

Unquote

By Order of the Board

Dr Daphne Šims Dodebier Company Secretary

Talk to a Data Expert

Have a question? We'll get back to you promptly.